FEMY (Femasys) Valuation Rank


FEMY Femasys Inc FEMY
55 GF Score
Price $3.80
GF Value $12.22
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Femasys Valuation Rank Related Terms

FEMY
55GF Score
Femasys Inc FEMY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $3.80 is trading 68.9% below its estimated GF Value™ of $12.22. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • Valuation Rank:
  • GF Value™: $12.22 vs. price of $3.80 (68.9% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score

Get the complete analysis for FEMY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price
$12.22
GF Value